cyrilzakka/clinical-trials huggingface dataset:
Clinical Research of Electro-acupuncture Combined Psychological Intervention on Internet Addiction Disorder

this research adopted multicentered, randomly and parallel control methods to observe the clinical effects of electro-acupuncture combined psychological intervention on internet addiction disorder, aim to provide a convenient, affordable and effective clinical protocol.

This research was aimed to discuss the impact of acupuncture treatment on the impulsive behavior of Internet Addiction Disorder (IAD) sufferers, with the detection of magnetic resonance spectroscopy (MRS), the assessment of Young's Internet Addiction Test (IAT), Barratt Impulsivity Scale (BIS-11) and Go/No-go task, hopefully that this research could provide basis for the further study as well as the establishment of comprehensive assessment and treatment protocol of IAD.

Eligibility Criteria:
Inclusion Criteria:

* Subjects manifested three or more among the seven following conditions within one year could be defined as internet addiction:
* (1) Tolerance, complied with either one: ①Satisfaction obtaining through markedly increasing time online ②Spending same period of time online but with dramatic declining satisfaction.
* (2) Any following symptoms appeared after quitting internet surfing: ①Obvious withdrawal syndrome: A-- Quitted or decreased long time internet surfing. B--Within one month after A, two or more following symptoms appeared: (a) Depressed. (b) Psychomotor fidgety. (c) Compulsively thought things happened online. (d) Hallucinated or dreamed about internet related stuff. (e) Consciously or unconsciously carried out tapping the keyboard movement. C--The symptoms in B led to unexpected damage to one's social life, work and other important aspects of life, even depression. ②Desperate to surf the internet or seek similar online service in a bid to relieve or avoid withdrawal syndrome.
* (3) More frequent online behaviors or longer online time than planned.
* (4) Had been trying hard to reduce or control internet use but never succeeded.
* (5) Spent large amount of time on internet related things, such as purchasing online books, trying out new browsers, organizing downloaded files, etc.
* (6) Giving up or reducing important social, work or entertainment activities.
* (7) Despite unfavorable physical, mental, social or work consequences, continued to use internet.

Exclusion Criteria:

* Other psychiatric disease history.
* Drug addiction history
* Severe cardiovascular disease, blood diseases, malignant tumors or any other contraindication of electro-acupuncture.
* Allergic to acupuncture treatment.
* Participants with intracranial diseases or abnormal scalp structure.
* Participants with metal implant.
* Color blindness, left handedness.
* Women in gestation or lactation period.
Serial Third Trimester Abdominal Circumference and Amniotic Fluid Measurements Versus Routine Care

The purpose of this study us to compare the rate of prenatal identification of abnormal fetal growth or amniotic fluid between clinical evaluation of uterine size by symphysis fundal height (SFH) measurements versus point-of-care ultrasound (POC-US) evaluation of abdominal circumference (AC) and maximum vertical pocket (MVP).


Eligibility Criteria:
Inclusion Criteria:

* Maternal age of 18 at the time of consent
* Singleton gestation
* Ultrasound examination that confirms or revises the estimated date of delivery (EDD) before 22 0/7 weeks of gestational age
* Gestational age ≥ 24 weeks gestation

Exclusion Criteria:

* Abnormal aneuploidy screening (1st trimester screening, 2nd trimester screening, integrated screening, NIPT)
* Fetal chromosomal or genetic abnormalities
* Fetal malformations or soft markers identified on fetal anatomy survey
* Current pregnancy is a result of in vitro fertilization
* Documented uterine bleeding after 24 weeks gestation. Unobserved self-reported bleeding with confirmed intact pregnancy on ultrasound after the bleeding episode is not an exclusion criterion.
* Uterine/placental abnormalities including uterine malformations (i.e bicornuate uterus, didelphus uterus), abnormal placentation (placenta previa, accrete, percreta), uterine fibroids.
* Cerclage in the current pregnancy
* History of intrauterine fetal demise
* Fetal isoimmunization or alloimmunization
* History of medical complications such as:

  * Cancer (including melanoma but excluding other skin cancers)
  * Endocrine disease including thyroid disease (recently diagnosed or whose medication dose is not stable), adrenal disease, diabetes mellitus (pregestational and gestational).
  * Renal disease with altered renal function (creatinine \> 0.9 or proteinuria)
  * Epilepsy or other seizure disorder
  * Any collagen disease (lupus erythematosus, scleroderma, etc.)
  * Active liver disease (acute hepatitis, chronic active hepatitis, persistently abnormal liver enzymes)
  * Hematological disorder including alloimmune and isoimmune thrombocytopenia but excluding mild iron deficiency anemia (Hb \> 9 gm/dl). Patients with sickle cell disease are excluded.
  * Chronic pulmonary disease including asthma requiring regular use of medication and active tuberculosis (TB). An asthma inhaler used on an as needed basis (PRN) for a cold or an asthma attack is not considered regular use.
  * Heart disease except mitral value prolapse not requiring medication
  * Cardiovascular disorders: chronic hypertension
  * Liver disorders accounting for cholestasis
  * Infectious diseases: HIV, Cytomegalovirus (CMV), toxoplasmosis, parvovirus B19
Fatigue and Exercise Training in Patients With Sarcoidosis

The aims of the current study is to explore if different exercise training protocols affect fatigue post-exercise, and if sarcoidosis-related fatigue and maximal and sub-maximal cardiopulmonary exercise test (CPET) variables change after a 4-weeks exercise training period.

This project aims to provide data on post-exercise fatigue after single exercise sessions with endurance training and muscle strength training, each with two different intensities. For endurance training; post-exercise fatigue will be assessed after one session of high intensity interval training, and one session with longer duration of moderate intensity. For muscle strength training, fatigue will be measured after one session with high loads/few repetitions and one session with low loads/many repetitions. In addition, changes in sub-maximal and maximal metabolic and ventilatory responses to a maximal cardiopulmonary exercise test on a treadmill (CPET) and association to sarcoidosis-related fatigue before and after a 4-weeks exercise training period will be studied.

Eligibility Criteria:
Inclusion Criteria:

* Patients with sarcoidosis diagnosed according to the latest American Thoracic Society/European Respiratory Society/World Association for Sarcoidosis and Other Granulomatous Disorders (ATS/ERS/WASOG) statement on sarcoidosis who are attending a four weeks exercise based pulmonary rehabilitation program at LHL-klinikkene Glittre.

Exclusion Criteria:

* Patients with a concurrent and predominant diagnosis of another significant respiratory disorder (for example: asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, or lung cancer).
* Unstable cardiovascular disease.
* Not able to perform the required physical tests and exercise training sessions caused by co-morbidities.
GERD Infant Feeding Therapeutics Trial (GIFT Trial)

The goal of this investigator-initiated, single-center, randomized controlled trial (RCT) is to compare the effects of four weeks of three therapies on clinical and mechanistic outcomes based on pH-Imp testing using a three-arm parallel design in NICU infants with objective GERD diagnosis. The three therapies being compared are natural maturation, proton pump inhibitor (PPI) use, and added rice (AR) formula use. The main goals are:

* to evaluate and compare the efficacy of the three commonly used treatment interventions used in the NICU for GERD in a randomized controlled manner with the primary endpoint of oral feeding success and absence of troublesome symptoms (as defined below).
* to characterize the mechanisms of primary end point (success or failure) using pH-Impedance metrics.

In consented subjects, eligibility is determined after initial diagnostic 24-hour pH Impedance test. These subjects will be randomized to one of the 3 arms of the study (natural maturation, PPI, AR formula) for 4 weeks of treatment. A second 24-hour pH Impedance test will be done on therapy at 4 weeks or before discharge, whichever occurs first. Primary outcome will also be measured at 4 weeks or at discharge, whichever comes first.

Eligibility Criteria:
Inclusion Criteria:

* NICU infants of any gestational age who are between 37 - 47 weeks postmenstrual age at inception of the study meeting the following requirements:

  * GERD diagnosis using pH-impedance criteria (Acid Reflux Index ≥ 3% plus at least one of the following: # GER events \>70 / day, Symptom Associated Probability ≥ 95%, Discal Baseline Impedance \< 900 Ω)
  * Full enteral feeds
  * No current GERD therapies

Exclusion Criteria:

* Known lethal chromosomal abnormalities or complex congenital syndromes
* Severe neurologic pathologies requiring neuroactive medications or neurosurgery
* Positive airway pressure or oxygen flow \> 4 LPM
* Upper gastrointestinal malformations requiring surgery
Multimodal Analgesia for the Reduction of Postoperative Opioid Consumption

The investigators are performing this research study to investigate the efficacy of local infiltration of the surgical wound combining dexmedetomidine, ropivacaine, and ketorolac (treatment group) versus the current standard of care (historical control group), for post-operative pain management.

During this research study, patients recommended for a rectus sheath block during surgery will receive a novel combination of non-opioid drugs. Data from the treatment group will be compared to surgical outcomes of a historically matched control group to investigate the ability of this drug combination to reduce post-operative pain and post-operative opioid consumption.

Eligibility Criteria:
Inclusion Criteria:

* Age greater than 18 years
* American Society of Anesthesiologist Physical Status Classification 1-3
* Undergoing surgery requiring a rectus sheath block

Exclusion Criteria:

* American Society of Anesthesiologist Physical Status Classification of 4 or beyond
* history of opiate of illicit substance abuse, chronic pain, or neurological dysfunction
Clinical Trial of DA-5212 in Patients with Functional Dyspepsia

This study is to evaluate efficacy and safety of DA-5212 in patients with functional dyspepsia


Eligibility Criteria:
Inclusion Criteria:

* Men or women ≥ 19 years of age
* Patients who diagnosed with functional dyspepsia
* Patients with no organic cause for digestive symptoms found by upper gastrointestinal endoscopy at screening visit

Exclusion Criteria:

* Patients with organic disease or medical history that may cause dyspepsia within 6 months before screening visit
* Patients who have a history of drugs or alcohol abuse and dependence within 6 months before screening visit
* Patients with hypersensitivity to investigational drugs and similar drugs
* Pregnant or breastfeeding women
Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging

Primary Objective:

* Evaluate the agreement between radionuclide ventriculography (RNV) and gated F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in calculating left ventricular ejection fraction (LVEF), end diastolic volume (EDV) and end systolic volume (ESV).

Your doctor has ordered a PET/CT scan and a NM scan on you for routine care. By agreeing to take part in this study, you will go through both of these procedures as you normally would.

For both imaging exams, you will be lying on your back. Every effort will be made to make you as comfortable as possible. For theNM cardiac scan, you will be hooked up to a heart monitor that will take a picture every time your heart beats. Your heart will be imaged from several different views. This exam will take about 30 minutes.

The PET/CT cardiac scan will be done after completion of your normally scheduled PET/CT scan. For this scan, you will be hooked to a heart monitor that records the beats of your heart. While this monitor is attached, you will be imaged with the PET/CT scanner. The PET/CT cardiac scan will take about 10-15 minutes after your PET/CT exam is completed.

Both imaging exams will provide a number that corresponds to the percent of blood pushed out of the left ventricle of your heart during a resting state.

Taking part in this study should add between 10-15 additional minutes to your PET/CT visit. This is due to the additional cardiac imaging time.

This is an investigational study. A total of up to 50 patients will take part in this study. All will be enrolled at UTMDACC.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing both FDG PET/CT scan and RNV within two weeks interval, whether for initial staging, restaging or to evaluate response to therapy.
* Patients who would consent to an additional 10-15 minutes acquisition of the gated images after completion of their FDG PET/CT study with the additional radiation exposure.
* Patients with regular heart rate.

Exclusion Criteria:

* Blood glucose level above 200 mg/dL.
* Irregular heart rate.
* An interval of less than 1 day between the FDG PET/CT scan and RNV.
Dynamic Quadriceps Muscle Stimulation for Treatment of Patellofemoral Pain

The purpose of this small, pilot study is to evaluate a novel device that uses neuromuscular electrical stimulation to assist quadriceps muscles as a user walks. This study will involve use of this device on individuals with patellofemoral pain, a relatively common injury among active people, to see if quadriceps stimulation could mitigate disparities in quadriceps activation timing that may indirectly lead to knee pain.

The interventional device will be tested with 20 women aged 18-40 with evidence of patellofemoral pain syndrome (PFPS) and without any co-morbidities that would confound data or contraindications for NMES use. All participants will be enrolled at a single site (Developmental Motor Lab at the University of Texas), and all of a single participant's testing will be complete within a single day with no requirement for follow-up or long-term participation. Participants will have their gait and quadriceps muscle activation patterns evaluated through four six-minute walk tests (6MWT). The first 6MWT will be without a device, second with a device worn but not activated, third with a device activated and stimulating quadriceps musculature, and the fourth without a device.

Primary Objective: The purpose of this study is to investigate whether electrical stimulation of the vastus medalis (VM) and/or vastus lateralis (VL) to establish coactivation of these muscles during terminal swing phase impacts severity of PFPS symptoms

Secondary Objectives: Secondary purposes for this study include evaluating KneeStim and seeing if there is any evidence of proof of concept in two main areas:

KneeStim as a therapeutic device that may assist individuals with joint rehabilitation KneeStim's on-board operating system and motion tracking system as an effective way to monitor joint kinematics.

This pilot study has a prospective, controlled, single-center design. Participants and investigators will not be blinded to the treatment. Individuals who evaluate the motion-tracking data between VICON and KneeStim will not be informed which data set aligns with which treatment.

Eligibility Criteria:
Inclusion Criteria:

* Aged 18-40 years
* Symptomatic PFPS on Patella Glide Test, Patella Tilt Test, and Patellar Apprehension Test.

Exclusion Criteria:

* Rheumatoid arthritis or inflammatory arthritis as assessed by licensed physician
* Use of walking aids other than a cane more than 50% of the time in ambulation
* Diagnosed knee disorder other than patellofemoral syndrome
* Pacemaker use, unstable angina, or decompensated heart failure
* Knee replaced in preceding 12 months or replacement planned within 6 months
* Moderate to severe dementia
* Pregnancy (self report)
* Altered sensation at the knee such that the patient is unable to perceive the presence of pinprick.
* Use of intra-articular viscosupplementation or steroid injection within preceding 2 months.
* Use of chronic anticoagulation medication.
* Movement-limiting pain in the back, hip, ankle, or foot of either lower limb.
The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD

The purpose of this study is to assess the efficacy and safety of Newrabell® Tab. in patients with refractory reflux esophagitis to the prior standard PPIs regimen.


Eligibility Criteria:
Inclusion Criteria:

1. Male or Female aged ≥ 20 years
2. Reflux esophagitis with erosion or ulceration confirmed by endoscopic exam.
3. Refractory reflux esophagitis to PPIs standard treatment as follows

   1. Ongoing heartburn symptom with or without these GERD-related symptoms : Regurgitation, Non-cardiac chest pain, Epigastric pain, Belching, Bloating, Satiety, Sore throat, Cough, Laryngitis, Hoarseness, Nausea, Vomiting, Dysphagia, Odynophagia, Weight loss
   2. Ongoing heartburn symptom with or without erosion ≥ grade A according to LA Classification
4. Ongoing heartburn symptoms ≥ 2 days during 1week right before administering first dose of IP
5. Decided to participate and signed on an informed consent form willingly

Exclusion Criteria:

1. Existence of upper gastrointestinal bleeding or active gastroduodenal ulcer at screening
2. History of operation in esophagus, stomach or duodenum
3. The following medical history

   1. Primary esophageal motility disease, Achalasia, Scleroderma, Esophageal/pyloric stricture, Primary esophageal spasm
   2. Barrett's esophagus ≥ 3 cm
   3. Zollinger-Ellison syndrome
   4. Infectious or inflammatory bowel disease, Severe malabsorption
4. Severe chronic heart failure, cardiovascular disease, renal failure, COPD, asthma, liver cirrhosis
5. History of cancer within 5 years, except completely recovered skin cancer
6. ALT or AST ≥ Upper limit of normal range X 3
7. Need antibiotics due to severe infection
8. Severe medical disease that needs these prohibited medication

   * Anticoagulant(Heparin, Warfarin, etc.), High dose of aspirin(\>325mg/d), Digitalis(Digoxin, etc.), Diuretics, Atazanavir, NSAIDs or Steroids
9. Use PPIs or H2RA medicine within 1 week before administering first dose of IP, or need other PPIs or H2RA medicine during trial period
10. Allergy or hypersensitivity to IP or similar chemical structure(Benzimidazol derivatives, etc.)
11. Pregnant or breast-feeding women
12. Conversation impairment because of alcohol, drug addiction or mental illness, etc.
13. Administration of other IP within 28 days
14. Inability to record heartburn diary card
15. In investigator's judgement
In Vitro Study of [18F]F-FAPI-74 Feasibility in Vulvar Cancer

This study aims to investigate the expression of FAP by phosphor imaging in invasive vulvar squamous cell carcinoma specimens. This in vitro study will include all consecutive tumour specimens stored both in optimal cutting temperature (OCT) compound and formalin-fixed paraffin-embedded (FFPE) from patients with a first diagnosis of vulvar squamous cell carcinoma who underwent surgery at Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Vulvar cancer is a rare gynaecological tumour, affecting 2.5 out of 100,000 women per year. The most common histological type is squamous cell carcinomas. Current guidelines suggest 2-\[18F\]fluoro-2-deoxy-D-glucose (\[18F\]FDG) PET/CT for T2 or larger tumours or when metastases are suspected, even though few studies showed controversial results on small series about the diagnostic accuracy of \[18F\]FDG PET/CT for vulvar cancer. The recently developed fibroblast activation protein inhibitor (FAPI), labelled with gallium-68 or fluorine-18, may be a promising diagnostic tool for gynaecological cancers in the field of PET/CT imaging. There is an unmet need to characterize FAP expression at the whole-body level, to assess target expression for disease detection and FAP-directed therapies. This study aims to investigate the expression of FAP by phosphor imaging in vulvar squamous cell carcinoma specimens on OCT compound and FFPE sections.

Eligibility Criteria:
Inclusion Criteria:

* Patients with histologically confirmed diagnosis of invasive vulvar cancer with squamous cell histotype, both from primary tumour site and excised metastatic LNs.
* Availability of both FFPE and OCT stored samples from each primary tumour site and (when available) from the corresponding metastatic groin lymph nodes.
* Samples stored in sufficient quantity not to be completely exhausted by their use for this study.
* Optimal stored sample
* Available clinical and histopathological data

Exclusion Criteria:

- Coexistence of primary tumours other than vulvar cancer
Venetoclax in Combination With Standard Induction and Consolidation Chemotherapy in Newly Diagnosed Young AML Patients

The goal of this observational study is to to evaluate the efficacy and safety of Venetoclax in combination with DA60(daunorubicin 60 mg/m2/d for 3 days, and cytarabine 100 mg/m2 every 12 h for 7 days) induction and HD-AraC(cytarabine 3 g/m2 every 12 h for 3 days) consolidation, in young patients with newly diagnosed acute myeloid leukemia (AML).


Eligibility Criteria:
Inclusion Criteria:

* Newly diagnosed, morphologically documented AML based on the World Health Organization (WHO) 2016 classification.
* Age ≥ 18 years and ≤ 59 years
* Have been treat with the "venetoclax in combination with standard induction and consolidation chemotherapy" therapy, and in follow-up.
* Be comprehensive of the research, and able to provide informed consent.

Exclusion Criteria:

* Diagnosis of acute promyelocytic leukemia (APL).
* Prior treatment for AML, except for: leukapheresis, hydroxyurea, and growth factor/cytokine.
* Unable to understand or participate.